Anagliptin vs Evogliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Anagliptin · Suiny
Marketed by Sanwa Kagaku Kenkyusho and partners
NCT01529541 · Phase 3 · completed
The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.
Next expected readout: March 2027 · NCT07442006 (registry estimate)
Reported efficacy
The Change in HbA1c from baseline to week24 (0wk, 8wk, 16wk, 24wk): HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. (met)
Result source: NCT01529528
Evogliptin · Suganon
Marketed by Dong-A ST and partners
NCT02949193 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial (n=222) comparing evogliptin against sitagliptin, both added to metformin. The prespecified non-inferiority comparison for the primary endpoint, HbA1c change at 24 weeks, was met: the between-group difference and its confidence interval stayed within the non-inferiority range.
Reported efficacy
Change from baseline in HbA1c (%) After 24 weeks: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001) (met)
Result source: NCT04170998
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Anagliptin | Evogliptin |
|---|---|---|
| HbA1c, change | -0.5% vs 0.2%a−0.7 vs placeboNCT015295282 other results
| -0.2% vs 0.1%a−0.3 vs placeboNCT029465412 other results
|
| Body weight, change (kg) | —Not posted · NCT01529528 | —Not posted · NCT02949193 |
| HbA1c below 7% | —Not posted · NCT01529528 | —Not posted · NCT02949193 |
| Fasting plasma glucose, change | —Not posted · NCT01529528 | —Not posted · NCT02949193 |
| 3-point MACE (% with event) | —Not posted · NCT01529528 | —Not posted · NCT02949193 |
HbA1c, change
- Anagliptin
- -0.5% vs 0.2%a−0.7 vs placeboNCT01529528
2 other results
- -0.5% vs 0.2% NCT01529528
- -0.8% vs -0.8% NCT01529541
- Evogliptin
- -0.2% vs 0.1%a−0.3 vs placeboNCT02946541
2 other results
- -0.6% vs -0.0% NCT04170998
- -0.6% vs -0.7% NCT02949193
Body weight, change (kg)
- Anagliptin
- —Not posted · NCT01529528
- Evogliptin
- —Not posted · NCT02949193
HbA1c below 7%
- Anagliptin
- —Not posted · NCT01529528
- Evogliptin
- —Not posted · NCT02949193
Fasting plasma glucose, change
- Anagliptin
- —Not posted · NCT01529528
- Evogliptin
- —Not posted · NCT02949193
3-point MACE (% with event)
- Anagliptin
- —Not posted · NCT01529528
- Evogliptin
- —Not posted · NCT02949193
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Evogliptin
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anagliptin's landscape · Evogliptin's landscape